Publicacións en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (35)

2024

  1. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

  2. Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO)

    Thrombosis Update, Vol. 17

  3. Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy

    Clinical and Translational Oncology

2023

  1. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  2. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

    Journal of Clinical Medicine, Vol. 12, Núm. 15

  3. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

  4. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

  2. BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up

    European Urology

  3. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  4. SEOM—GECOD clinical guideline for unknown primary cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 681-692

2020

  1. Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies

    Frontiers in Oncology, Vol. 10

  2. Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression

    Journal of Urology

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  2. CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 390-402

  3. Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status

    Scientific Reports, Vol. 9, Núm. 1

  4. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine

2018

  1. The Ras-related gene ERAS is involved in human and murine breast cancer

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer

    Clinical Cancer Research, Vol. 23, Núm. 23, pp. 7388-7399

  2. Epigenetic mutations and cancer therapy Effectiven(EZH2)

    Translational Cancer Research